AstraZeneca rejected Pfizer Inc. (NYSE:PFE)’s sweetened takeover proposal Friday, saying the $105.6 billion offer fails to appreciate the value of the promising medicines under development by the U.K.’s second-biggest drugmaker. Pfizer Inc. (NYSE:PFE) stock opened at $31.02 in last session, and closed at $30.75, while the day range of PFE stock is $30.55 – $31.06. The stock showed a negative weekly performance of -1.28%.
Shares of Endocyte Inc (NASDAQ:ECYT) saw strong trading volume on Friday after the company announced better than expected quarterly earnings, American Banking and Market News reports. 13,778,961 shares changed hands during trading, an increase of 624% from the previous session’s volume of 1,903,723 shares. Several analysts have recently commented on the stock. Analysts at Brean Capital cut their price target on shares of Endocyte Inc. (NASDAQ:ECYT) from $41.00 to $22.00 in a research note on Friday. They now have a “buy” rating on the stock. Separately, analysts at Piper Jaffray downgraded shares of Endocyte Inc. (NASDAQ:ECYT) from an “overweight” rating to a “neutral” rating in a research note on Friday. Endocyte, Inc. (NASDAQ:ECYT) stock opened at $6.75, in last session and closed at $6.62, by losing -61.91%. The 52 week range of ECYT is $6.50 – $33.70. Company’s market capitalization is $273.61million.
Boston Scientific Corporation (NYSE:BSX) has launched the Promus PREMIER Everolimus-Eluting Platinum Chromium Coronary Stent System in Japan. This advanced DES system recently received Japan Ministry of Health, Labor and Welfare (MHLW) approval. “It is my great pleasure to be able to provide the Promus PREMIER Stent System to physicians and patients in Japan,” said Yusuke Naiki, president and representative director for Boston Scientific Corporation (NYSE:BSX) Japan K.K. “This innovative stent enhances our portfolio of coronary intervention products, and we believe it will strengthen our position in Japan’s DES market.” Boston Scientific Corporation (NYSE:BSX) stock advanced 1.67% and finished the last session at $12.81. The EPS of the stock remained -0.09. Company’s market capitalization is $16.94billion.
Health care companies should report a 10.8% earnings growth on a 7.8% sales gain. Gilead Sciences Inc. (NASDAQ:GILD) tripled earnings on its $84,000 hepatitis C drug. Gilead Sciences, Inc. (NASDAQ:GILD) stock opened the session at $79.30, and closed the session at $77.71. The 52 week range of the GILD stock remained $46.70 – $84.88 and the day range was $76.65 – $79.50.